Literature DB >> 326550

Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia.

L Brandt, I Könyves.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326550     DOI: 10.1016/0014-2964(77)90088-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  7 in total

Review 1.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  [Acute leukemias in elderly patients (author's transl)].

Authors:  K Grünewald; K Abbrederis; P Mittermaier; H Huber
Journal:  Blut       Date:  1982-05

3.  Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung.

Authors:  H S Jensen; H H Hansen; P Dombernowsky
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia.

Authors:  B Lönnqvist; B Andersson; M Björkholm; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; H Mellstedt; J Palmblad; C Paul; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Prednimustine in adult acute myeloid leukaemia.

Authors:  L Brandt; I Könyves
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.

Authors:  D R Gandara; C A Ries; S A Schiff; C B George; J P Lewis; M M Koretz; S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.